APA (7th ed.) Citation

M, Z., V, G., AK, S., EMEA, L., C, M., WF, B., . . . ACZ, G. (2025). Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120). Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 50(6), e20240228. https://doi.org/10.36416/1806-3756/e20240228

Chicago Style (17th ed.) Citation

M, Zukin, et al. "Durvalumab as Consolidation Therapy in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real-world Data from an Expanded Access Program in Brazil (LACOG 0120)." Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia 50, no. 6 (2025): e20240228. https://doi.org/10.36416/1806-3756/e20240228.

MLA (9th ed.) Citation

M, Zukin, et al. "Durvalumab as Consolidation Therapy in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real-world Data from an Expanded Access Program in Brazil (LACOG 0120)." Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia, vol. 50, no. 6, 2025, p. e20240228, https://doi.org/10.36416/1806-3756/e20240228.